Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Bright future or blind alley? CAR-T cell therapy for solid tumors

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR-T in solid tumors: Blazing a new trail through the brambles

A long way to the battlefront: CAR T cell therapy against solid cancers.

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Innovative Strategies to Advance CAR T Cell Therapy for Solid Tumors.

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

Hurdles of CAR-T Cell-Based Cancer Immunotherapy Directed Against Solid Tumors.

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

CAR T cells in solid tumors: challenges and opportunities

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Current Progress in CAR-T Cell Therapy for Solid Tumors

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

Prospects and challenges for use of CAR T cell therapies in solid tumors

Current progress in CAR-T cell therapy for tumor treatment

Target Selection of CAR T Cell Therapy in Accordance with the TME for Solid Tumors.

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment